Dos Santos G. et al. Immunogenicity, safety, and effectiveness of seasonal influenza vaccination in patients with diabetes mellitus: A systematic review. Hum Vaccin Immunother. 2018.
Amos AF. et al. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997.
Casqueiro J. et. al. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian Journal of Endocrinology and Metabolism / 2012 / Vol 16 / Supplement 1.
Goeijenbier M. et. al. Benefits of flu vaccination for persons with diabetes mellitus: A review. Vaccine 35 (2017) 5095–5101.
Papagianni M. et al. Herpes Zoster and Diabetes Mellitus: A Review. Diabetes Ther (2018) 9:545–550.
Shah BR. et al. Quantifying the Risk of Infectious Diseases for People With Diabetes. Diabetes Care 26:510–513, 2003.
Lau D. et al. Working-age adults with diabetes experience greater susceptibility to seasonal influenza: a population-based cohort study. Diabetologia (2014) 57:690–698.
Allard R. et al. Diabetes and the Severity of Pandemic Influenza A (H1N1) Infection. Diabetes Care 33:1491–1493, 2010.
Mertz D. et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ 2013;347:f5061.
Istituto Superiore di Sanità. Monitoraggio dell’andamento delle forme gravi e complicate di influenza confermata (2017-18). http://www.epicentro.iss.it/problemi/influenza/FluNews/FluNews_2018-17.pdf
Piano Nazionale Prevenzione Vaccinale (PNPV) 2017-19. 18-2-2017.
Ministero della Salute. Direzione Generale della Prevenzione Sanitaria. Prevenzione e controllo dell’influenza: raccomandazioni per la stagione 2018-2019. 30 maggio 2018.
AMD e SID: Standard Italiani per la Cura del Diabete Mellito 2018.
Kwong JC. et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med 378;4. January 2018.
MacIntyre CR. et al. Influenza vaccine as a coronary intervention for prevention of myocardial infarction. Heart 2016;102:1953–1956.
Colquhoun AJ. et al. Effectiveness of infuenza vaccine in reducing hospital admissions in people with diabetes. Epidemiol. Infect. (1997), 119, 335±341.
Vamos EP. et al. Effectiveness of the influenza vaccine in preventing admission to hospital and death in people with type 2 diabetes. CMAJ, October 4, 2016, 188(14).
Kuan Wang I. et al. Effectiveness of influenza vaccination in elderly diabetic patients: A retrospective cohort study. Vaccine 31 (2013) 718– 724.
Sheridan PA. et al. The antibody response to influenza vaccination is not impaired in type 2 diabetics. Vaccine. 2015 June 26; 33(29): 3306–3313.
Sistema Sorveglianza PASSI. Coperture vaccinali antinfluenzale malati cronici adulti (18-64 anni). www.epicentro.iss.it/passi/dati/VaccinazioneAntinfluenzale.asp
Jiménez-Garcia R. et al. Influenza vaccination in people with type 2 diabetes, coverage, predictors of uptake, and perceptions. Result of the MADIABETES cohort a 7 years follow up study. Vaccine 35 (2017) 101–108.
Verger P. et al. Characteristics of patients and physicians correlated with regular influenza vaccination in patients treated for type 2 diabetes: a follow-up study from 2008 to 2011 in southeastern France. Clin Microbiol Infect 2015; 21: 930.e1–930.e9.
2017 Censis report: la vaccinazione antinfluenzale nel nuovo assetto demografico.
Torres A. et al. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax 2015;0:1–6.
Suaya JA. et al. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults. Vaccine 36 (2018) 1477–1483.
Lopez-de-Andres A. et al. Hospitalisation with community acquired pneumonia among patients with type 2 diabetes: an observational population-based study in Spain from 2004 to 2013. BMJ Open 2017;7:e013097
Sheng Kuo C. et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly. Medicine (2016) 95:26
Beam TR. et al. Antibody response to polyvalent polysaccharide vaccine in diabetics. JAMA. 1980 Dec 12;244(23):2621-4.
Friedman EA. et al. Intact antibody response to pneumococcal capsular polysaccharide in uremia and diabetes. JAMA. 1980 Nov 21;244(20):2310-1.
Geerlings SE. et al, Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunology and Medical Microbiology 26 (1999) 259^265.
Blasi F. et al. VACCINAZIONE ANTIPNEUMOCOCCICA NEGLI ADULTI: RACCOMANDAZIONI DELLA SOCIETÀ ITALIANA DI MEDICINA RESPIRATORIA (SIMeR) E DELLA SOCIETÀ ITALIANA DI IGIENE, MEDICINA PREVENTIVA E SANITÀ PUBBLICA (SItI). Epidemiol Prev 2014; 38(6) Suppl 2: 1-158.
Clancy U. et al. Prevalence and predictors of influenza and pneumococcal vaccine uptake in patients with diabetes. Ir Med J. 2012 Oct; 105(9):298-300.
Alvarez CE. aet al. Survey of vaccination practices in patients with diabetes: A report examining patient and provider perceptions and barriers. Journal of Clinical & Translational Endocrinology 9 (2017) 15–17.
Kawai K. et al. Risk Factors for Herpes Zoster: a Systematic Review and Meta-analysis. Mayo Clin Proc. 2017. Dec 92(12):1806-1821.
Suaya JA. et al. Incidence of Herpes Zoster and Persistent Post-Zoster Pain in Adults With or Without Diabetes in the United States. Open Forum Infectious Diseases 2014 Aug 2; 1(2).
Weitzman D. et al. A population based study of the epidemiology of Herpes Zoster and its complications. Journal of Infection (2013) 67, 463e469.
Centers for Disease Control and prevention (CDC). Seasonal Influenza (Flu). https://www.cdc.gov/flu/diabetes/index.htm